October 3, 2018
The Changing of the Guard at Pfizer: What Does It Mean?
by Patricia Van Arnum, DCAT Editorial Director
Pfizer announced that Ian Read, current Chairman and CEO of Pfizer, will step down as CEO January 1, 2019 to be succeeded as CEO by Albert Bourla, the company’s current chief operating officer. Does the changing of the guard mean a shift in strategy? DCAT Value Chain Insights takes an inside look. 

Tracking Generic-Drug Approvals in the US
by Patricia Van Arnum, DCAT Editorial Director

In 2017, the FDA approved the most generic-drug applications ever, 1,027 abbreviated new drug applications (ANDAs), breaking the previous record high set in 2016 by 214 approvals when the FDA approved 813 ANDAs. So how are generic-drug approvals faring thus far in 2018? 

Don't Miss Top Industry News online and in your inbox every Friday
About the Editor
Patricia Van Arnum has more than 20 years of experience as a business and science editor, covering the chemical, pharmaceutical, biopharmaceutical, and fine-chemicals industries. Ms. Van Arnum was Executive Editor of  Pharmaceutical Technology  from 2006 to 2014 and Executive Editor of  ICIS Chemical Business  and  Chemical Market Reporter  ( CMR ) from 1995 to 2005.
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association .
To learn more, please visit www.dcat.org .